Özet
Amaç
Bu çalışmanın amacı, interstisyel akciğer hastalığı (İAH) olan Sjögren hastalığı (SH) hastalarda parotis bezi ultrasonografisi bulgularını değerlendirmek ve bu bulguları İAH olmayan SH hastaları ile karşılaştırmaktır.
Yöntem
Bu tek merkezli, kesitsel çalışmaya SH’ye bağlı İAH tanısı olan 20 hasta ve İAH olmayan 110 SH hastası dahil edildi. Parotis bezi ultrasonografisi bulguları, Romatolojide Sonuç Ölçümleri (OMERACT) yarı-kantitatif skorlama sistemine (derece 0-3) göre değerlendirildi. Parotis bezi ultrasonografisi bulguları ile birlikte grupların klinik ve laboratuvar özellikleri karşılaştırıldı.
Bulgular
Gruplar arasında ortalama yaş ve tanı yaşı açısından istatistiksel olarak anlamlı fark saptanmadı (p>0.05). Ancak erkek hasta oranı, İAH grubunda İAH olmayan gruba kıyasla anlamlı derecede daha yüksekti (%20,0 vs. %1,9; p=0,005). Birincil sonuçlar açısından, SH’ye bağlı İAH olan hastalarda parotis bezi ultrasonografisi skorlarının daha hafif olduğu görüldü. Her iki parotis bezinde toplam OMERACT skoru ≥2 olan hasta oranı, İAH grubunda İAH olmayan gruba göre anlamlı olarak daha düşüktü (%65,0 vs. %84,5; p=0,03). İkincil bir bulgu olarak, tanı anında İAH grubundaki hastaların %70’inde (n=14) baskın semptomların pulmoner tutulum ile ilişkili olduğu, yalnızca %30’unda ise kuruluk (sikka) semptomlarının ön planda olduğu saptandı.
Sonuç
Bu çalışma, SH’ye bağlı İAH’si olan hastaların sicca semptomlarından ziyade pulmoner semptomlarla daha sık başvurduğunu ve parotis bezi ultrasonografik tutulumunun daha hafif olduğunu göstermektedir. Bu bulgular, SH’ye bağlı İAH’nin nispeten düşük dereceli parotis bezi ultrasonografik değişiklikleri ile karakterize ayrı bir klinik alt grup olabileceğini düşündürmektedir.
Anahtar Kelimeler:
İnterstisyel akciğer hastalığı, ultrasonografi, Sjögren hastalığı, parotis bezi
Kaynaklar
1Mariette X, Criswell LA. Primary Sjögren’s syndrome. N Engl J Med. 2018;378:931-9.
2Koh JH, Park Y, Lee J, et al. Long-term outcome of interstitial lung disease in patients with primary Sjögren’s syndrome: a retrospective observational study. Korean J Intern Med. 2025;40:148-159.
3La Rocca G, Ferro F, Bulleri A, et al. Glandular involvement in primary Sjögren’s syndrome patients with interstitial lung disease-onset and sicca-onset, a single centre cross-sectional study. Clin Exp Rheumatol. 2022;40:2344-9.
4Nannini C, Jebakumar AJ, Crowson CS, Ryu JH, Matteson EL. Primary Sjogren’s syndrome 1976-2005 and associated interstitial lung disease: a population-based study of incidence and mortality. BMJ Open. 2013;3:e003569.
5Gao H, Zou YD, Zhang XW, et al. Interstitial lung disease in non-sicca onset primary Sjögren’s syndrome: a large-scale case-control study. Int J Rheum Dis. 2018;21:1423-9.
6Manfredi A, Sebastiani M, Cerri S, et al. Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement. Clin Rheumatol. 2017;36:1261-8. Erratum in: Clin Rheumatol. 2017;36:1931.
7Zhang X, Feng R, Zhao J, et al. Salivary gland ultrasonography in primary Sjögren’s syndrome from diagnosis to clinical stratification: a multicentre study. Arthritis Res Ther. 2021;23:305.
8Shiboski CH, Shiboski SC, Seror R, et al.; International Sjögren’s Syndrome Criteria Working Group. 2016 American College of Rheumatology/European League against rheumatism Classification Criteria for primary Sjögren’s syndrome: a consensus and data-driven methodology involving three international patient Cohorts. Arthritis Rheumatol. 2017;69:35-45.
9Jousse-Joulin S, D’Agostino MA, Nicolas C, et al. Video clip assessment of a salivary gland ultrasound scoring system in Sjögren’s syndrome using consensual definitions: an OMERACT ultrasound working group reliability exercise. Ann Rheum Dis. 2019;78:967-73.
10Bellia M, Cannizzaro F, Scichilone N, et al. HRCT and scleroderma: semiquantitative evaluation of lung damage and functional abnormalities. Radiol Med. 2009;114:190-203. English, Italian.
11American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165:277-304. Erratum in: Am J Respir Crit Care Med. 2002;166:426.
12Raghu G, Remy-Jardin M, Myers JL, et al.; American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198:e44-68.
13Chen T, Yin CS, Wang P, et al. Differences between patients with probable UIP and definite UIP on HRCT in idiopathic pulmonary fibrosis: a real-world cohort study. J Clin Med. 2024;13:7170.
14La Rocca G, Ferro F, Sambataro G, et al. Primary-Sjögren’s-syndrome-related interstitial lung disease: a clinical review discussing current controversies. J Clin Med. 2023;12:3428.
15He C, Chen Z, Liu S, Chen H, Zhang F. Prevalence and risk factors of interstitial lung disease in patients with primary Sjögren’s syndrome: a systematic review and meta-analysis. Int J Rheum Dis. 2020;23:1009-18.
16Berardicurti O, Marino A, Genovali I, et al. Interstitial lung disease and pulmonary damage in primary Sjögren’s syndrome: a systematic review and meta-analysis. J Clin Med. 2023;12:2586.
17Ramírez Sepúlveda JI, Kvarnström M, Eriksson P, et al.; DISSECT consortium. Long-term follow-up in primary Sjögren’s syndrome reveals differences in clinical presentation between female and male patients. Biol Sex Differ. 2017;8:25.
18Verstappen GM, Pringle S, Bootsma H, Kroese FGM. Epithelial-immune cell interplay in primary Sjögren syndrome salivary gland pathogenesis. Nat Rev Rheumatol. 2021;17:333-48.
19Sato-Fukuba M, Arakaki R, Ushio A, et al. CD4 + T-cell-dependent differentiation of CD23 + follicular B cells contributes to the pulmonary pathology in a primary Sjögren›s syndrome mouse model. Front Immunol. 2023;14:1217492.
20Palm O, Garen T, Berge Enger T, et al. Clinical pulmonary involvement in primary Sjogren’s syndrome: prevalence, quality of life and mortality--a retrospective study based on registry data. Rheumatology (Oxford). 2013;52:173-9.
21Inanc N, Şahinkaya Y, Mumcu G, et al. Evaluation of salivary gland ultrasonography in primary Sjögren’s syndrome: does it reflect clinical activity and outcome of the disease? Clin Exp Rheumatol. 2019;37(Suppl 118):S140-5.
22Dong X, Zhou J, Guo X, et al. A retrospective analysis of distinguishing features of chest HRCT and clinical manifestation in primary Sjögren’s syndrome-related interstitial lung disease in a Chinese population. Clin Rheumatol. 2018;37:2981-8.
23Morita H, Shimizu Y, Nakamura Y, et al. Auto-antibody evaluation in idiopathic interstitial pneumonia and worse survival of patients with Ro52/TRIM21auto-antibody. J Clin Biochem Nutr. 2020;67:199-205.
24Jousse-Joulin S, Devauchelle-Pensec V, Cornec D, et al. Brief Report: ultrasonographic assessment of salivary gland response to rituximab in primary Sjögren’s syndrome. Arthritis Rheumatol. 2015;67:1623-8.
25Fisher BA, Everett CC, Rout J, et al. Effect of rituximab on a salivary gland ultrasound score in primary Sjögren’s syndrome: results of the TRACTISS randomised double-blind multicentre substudy. Ann Rheum Dis. 2018;77:412-6.
